Raffaella Giancola

Pescara, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

CAR-T TEMRA and CAR-Tregs in vivo expansion are both associated with a poor response after CD19.CAR-T therapy.

CAR-T TEMRA and CAR-Tregs in vivo expansion are both associated with a poor response after CD19.CAR-T therapy.

Journal: Bone marrow transplantation

Published: April 10, 2026

CD19.CAR T-cell-derived extracellular vesicles express CAR and kill leukemic cells, contributing to antineoplastic therapy.

CD19.CAR T-cell-derived extracellular vesicles express CAR and kill leukemic cells, contributing to antineoplastic therapy.

Journal: Blood advances

Published: September 18, 2024

Case Report: Invasive fungal infection after anti-CD19 CAR-T cell therapy. Implication for antifungal prophylaxis.

Case Report: Invasive fungal infection after anti-CD19 CAR-T cell therapy. Implication for antifungal prophylaxis.

Journal: Frontiers in immunology

Published: August 04, 2023

A pro-inflammatory environment in bone marrow of Treg transplanted patients matches with graft-versus-leukemia effect.

A pro-inflammatory environment in bone marrow of Treg transplanted patients matches with graft-versus-leukemia effect.

Journal: Leukemia

Published: January 21, 2023

CD200 as a Potential New Player in Inflammation during Rotator Cuff Tendon Injury/Repair: An In Vitro Model.

CD200 as a Potential New Player in Inflammation during Rotator Cuff Tendon Injury/Repair: An In Vitro Model.

Journal: International journal of molecular sciences

Published: October 07, 2022

Comparison between peripheral blood progenitor cell collection on the 4th or 5th day of granulocyte colony-stimulating factor treatment in allogeneic stem cell donors: implications for hematopoietic progenitor cell apheresis guidelines.

Comparison between peripheral blood progenitor cell collection on the 4th or 5th day of granulocyte colony-stimulating factor treatment in allogeneic stem cell donors: implications for hematopoietic progenitor cell apheresis guidelines.

Journal: Blood transfusion = Trasfusione del sangue

Published: February 02, 2022

NOTCH1 Activation Negatively Impacts on Chronic Lymphocytic Leukemia Outcome and Is Not Correlated to the NOTCH1 and IGHV Mutational Status.

NOTCH1 Activation Negatively Impacts on Chronic Lymphocytic Leukemia Outcome and Is Not Correlated to the NOTCH1 and IGHV Mutational Status.

Journal: Frontiers in oncology

Published: February 16, 2021

NOTCH1 inhibition prevents GvHD and maintains GvL effect in murine models.

NOTCH1 inhibition prevents GvHD and maintains GvL effect in murine models.

Journal: Bone marrow transplantation

Published: January 29, 2021

Clinical-Grade Expanded Regulatory T Cells Are Enriched with Highly Suppressive Cells Producing IL-10, Granzyme B, and IL-35.

Clinical-Grade Expanded Regulatory T Cells Are Enriched with Highly Suppressive Cells Producing IL-10, Granzyme B, and IL-35.

Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

Published: June 05, 2020

NOTCH and Graft-Versus-Host Disease.

NOTCH and Graft-Versus-Host Disease.

Journal: Frontiers in immunology

Published: March 30, 2018

NOTCH1 Is Aberrantly Activated in Chronic Lymphocytic Leukemia Hematopoietic Stem Cells.

NOTCH1 Is Aberrantly Activated in Chronic Lymphocytic Leukemia Hematopoietic Stem Cells.

Journal: Frontiers in oncology

Published: January 26, 2018

Treg-protected donor lymphocyte infusions: a new tool to address the graft-versus-leukemia effect in the absence of graft-versus-host disease in patients relapsed after HSCT.

Treg-protected donor lymphocyte infusions: a new tool to address the graft-versus-leukemia effect in the absence of graft-versus-host disease in patients relapsed after HSCT.

Journal: International journal of hematology

Published: February 07, 2017

Showing 1-12 of 17

Last Updated: 09/26/2026